Abstract
The aim of this research is to evaluate the prevalence of HGV among three different categories, group1, composed of hepatitis –B patients (HB- patients), group 2, included people having hepatitis-like symptoms with sera negative for HBV and HCV markers, referred to as suspected for hepatitis (SUS-patients) while the third group is the control group. Serum samples were assayed for anti-HGV antibodies using ELISA technique-indirect method. Results revealed that HGV coinfection detected in only few number of HB-P 9.8%, 23.5% of HB-P having anti-HGV antibodies with titer lower than the cut-off value (COV) which are said to be in the shadow zone and the other 66.6% of the group are reported as negative cases, reporting a highly significant difference P˂0.001. Among the second group (SUS- patients), HGV was detected in only 4.8%, 58.5% detected as shadow cases while the other 36.5% were found to be negative for HGV.When both HB-P and SUS-P are gathered in one group a low percentage 7.6% of HGV infection was recorded, 39.1% of HB-/SUS-patients were in the shadow zone while the majority of this group 53.2% were detected as negative cases. In conclusion HGV play only a minor role as a confection agent with HBV and as a responsible agent among non-A-E hepatitis cases. Remarkable high percentages of shadow cases are reported in the three groups especially among non-A-E hepatitis patients.
Highlights
Two novel Flavi viruses were identified in 1990s by two independent groups of researchers; GBV-C was first identified in the sera of West African population during an attempt to retrospective track down the causative agent of an incident acute hepatitis in a sergeon
Materials and methods A total of 108 blood samples were collected from three different categories, the first studied group was the hepatitis-B patients (HB-P), the second group included patients with a history of blood transfusion, having hepatitis symptoms like jaundice, light stool and dark urine color and their sera found to be negative for HBV and HCV, so they were designated as suspected for parenterally-hepatitis (PT-hepatitis)such patients referred to as(SUS-P) and the third studied group was the control group, consisted of healthy blood donors
Sensitive tests for detection of knew hepatitis viruses are available, the etiology of 10-15% post transfusion and community acquired hepatitis cases has remained undefined suggesting the existence of unknown causative agents associated with this disease, hepatitis-G- virus (HGV)/GBV-C was newly discovered as putative non A-E hepatitis viruses [10]
Summary
Two novel Flavi viruses were identified in 1990s by two independent groups of researchers; GBV-C was first identified in the sera of West African population during an attempt to retrospective track down the causative agent of an incident acute hepatitis in a sergeon. The second studied category consisted from people having hepatitis-like symptoms but their sera detected as negative for HBV and HCV markers(HBs- Ag and anti-HCV Abs) with a history of maintenance blood transfer, their total number is 82, age ranging 11-35, age mean 33±5.2, M:F ratio was 1:4.8. Results revealed that 4 out of 82(4.87%) of the whole number of this group found to be infected with HGV, 48 out of 82 (58.5%) having anti-HGV antibodies but their titer did not reach up to the COV so they still in the shadow region, while 30 out of 82 (36.5%) were negative for HGV antibodies Among this category most of the patients were in the shadow region, a highly significant difference was recorded PSC DF-2=38.8, P0.001. Most of them were in the SUS-P 58%, HB-P 23.5% and controls 33.33%, a highly significant difference was reported, PCS DF-2=19.9, P0.001 table (1)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
